PQCA

Research use only, not for human use.

PQCA is a muscarinic M1 receptor-positive allosteric regulator, which is highly selective and effective.

PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA has an EC50 value of 49 nM and 135 nM on rhesus and human M1 receptor, respectively.PQCA is inactive for other muscarinic receptors. PQCA has potential to reduce the cognitive deficits associated with Alzheimer's disease.

——

PQCA (3-30 mg/kg; oral administration; single- or pair-housed male rhesus monkeys) treatment attenuates the scopolamine deficits in PAL and CPT tasks. Blockade of muscarinic signaling by scopolamine produces significant impairments in both tasks.Animal Model:Ten single- or pair-housed male rhesus monkeys (6-10 years old; 5.2-10.5 kg) with scopolamine Dosage:3 mg/kg, 10 mg/kg, or 30 mg/kg Administration:Oral administration Result:Attenuated the scopolamine deficits in paired-associates learning (PAL) and the continuous-performance task (CPT).

——

Cell Cycle/DNA Damage

AChR

AChR

——

——

1144504-35-7

388.42

C22H20N4O3

>98% (HPLC)

In Vitro:?DMSO : 10 mg/mL (25.75 mM; Ultrasonic (<80°C)

OC(=O)c1cc(CN2CCC(CC2)(C#N)c2ccccn2)c2ccccn2c1=O

——

(-20℃)

With Ice Pack

≥ 2 years